Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in refractory and relapsing multiple myeloma.

J Bladé1, J Esteve, L Rosiñol

  • 1Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain.

Seminars in Oncology
|December 12, 2001
PubMed
Summary

Thalidomide shows promise for patients with refractory multiple myeloma (MM). In a study of 23 patients, 52% experienced a response, indicating its potential as a treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.

Bone marrow transplantation·2020
Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017
Same author

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Younger Adults: Preliminary Results of a Study Based on 454 Patients-IWCLL/Working Group.

Leukemia & lymphoma·2016

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Multiple myeloma (MM) refractory to chemotherapy has limited treatment options.
  • Supportive measures offer minimal benefit, and survival is typically short.
  • Thalidomide has emerged as a potential therapeutic agent for refractory MM.

Purpose of the Study:

  • To evaluate the efficacy and safety of thalidomide in patients with advanced, refractory multiple myeloma.
  • To determine response rates and identify potential toxicities associated with thalidomide treatment.

Main Methods:

  • Twenty-three patients with advanced MM (16 refractory, 7 untested relapse) received thalidomide.
  • Doses ranged from 200 to 800 mg/day, typically divided into two doses.
  • Patient responses were assessed by changes in serum monoclonal (M)-protein levels.

Related Experiment Videos

Main Results:

  • Overall response rate was 52% (12 out of 23 patients).
  • Three patients (13%) achieved a partial response (>50% M-protein reduction).
  • Nine patients (39%) achieved a minimal response (>25% M-protein reduction).
  • Five patients discontinued treatment due to toxicity.

Conclusions:

  • Thalidomide demonstrates significant antitumor activity in patients with refractory multiple myeloma.
  • The drug is generally well-tolerated, although toxicity can necessitate treatment discontinuation.
  • Thalidomide represents a viable treatment option for patients with limited therapeutic alternatives.